Andre the Giant and Acromegaly: What Clinicians Should Tell Patients

Why Andre the Giant's Case Still Matters in 2025

Patients and trainees frequently bring up Andre the Giant when discussing growth hormone disorders. His story is not gossip. It is a historically grounded illustration of what progressive, untreated acromegaly does to the cardiovascular system, the skeleton, and soft tissue over four decades.

Andre René Roussimoff was born in Molien, France in 1946. By adolescence he reportedly could not fit in a school bus, and friends of the family noticed classical features of GH excess: coarsening facial features, enlarged hands and feet, and progressive jaw protrusion. No confirmed medical records have been made public, so the diagnosis of acromegaly is a clinical inference widely accepted by endocrinologists who have reviewed his photographs and documented history. Label it as such when speaking to patients.

He died on January 27, 1993, of congestive heart failure at age 46, in Paris. Cardiovascular disease is the leading cause of excess mortality in acromegaly, accounting for approximately 60% of acromegaly-related deaths [1].

The Diagnostic Delay Problem

The average delay from symptom onset to acromegaly diagnosis is still 5 to 10 years in modern practice [2]. Andre almost certainly had no formal diagnosis. In the 1950s through 1970s, transsphenoidal microsurgery was just beginning to be refined, MRI did not exist, and octreotide (approved by the FDA in 1988) was decades away.

That lag mirrors what patients face today. The Endocrine Society's 2014 Clinical Practice Guideline on Acromegaly states: "We recommend measuring serum IGF-1 in patients with typical clinical features of acromegaly." [3] Typical features include enlarged hands and feet, jaw protrusion, widened teeth spacing, soft-tissue swelling, hyperhidrosis, and new-onset sleep apnea. All of these were visible in Andre by his early twenties based on photographic and journalistic records.

What Clinicians Should Say When a Patient Mentions Andre

Keep the clinical frame. A practical script: "Andre the Giant's body changed the way it did because his pituitary gland produced far too much growth hormone, probably from a benign tumor. Today we catch that with a blood test called IGF-1 and confirm it with an MRI of the pituitary. We have medications that can normalize GH within months."

Avoid speculation about his personal health choices or suffering. The record is limited. Confine teaching points to documented physiology and modern treatment options.

Pathophysiology: GH Excess and Its Systemic Consequences

A GH-secreting pituitary somatotroph adenoma drives excess GH secretion, which stimulates hepatic IGF-1 production. IGF-1, not GH itself, mediates most of the somatic growth and metabolic effects [4]. In adults whose epiphyses have closed, excess GH causes acromegaly rather than gigantism. Andre's extraordinary height suggests GH excess began before epiphyseal fusion, producing true pituitary gigantism that then transitioned into acromegaly.

Cardiovascular Effects

Acromegalic cardiomyopathy is a distinct entity. GH and IGF-1 receptors are expressed in cardiomyocytes, and chronic excess produces biventricular hypertrophy, diastolic dysfunction, and eventually systolic failure [1]. A meta-analysis covering 1,362 acromegaly patients found left ventricular mass index elevated in 82% of subjects with active disease [5].

Andre's death from congestive heart failure at 46 fits this pattern precisely. He had no confirmed arrhythmia workup in the public record, but acromegaly also doubles the risk of atrial fibrillation, which could have contributed [5].

Skeletal and Soft-Tissue Effects

GH excess after epiphyseal closure drives periosteal bone formation rather than longitudinal growth. The result is bony enlargement of the jaw (prognathism), supraorbital ridges, hands, and feet, along with soft-tissue hypertrophy. Weight-bearing joints develop secondary osteoarthritis at accelerated rates. Andre reportedly required custom rings and shoes throughout his career, consistent with this progression.

Patients often ask whether Andre's size was "just genetics." The answer is no. Familial tall stature does not produce jaw overgrowth, shoe-size progression in adulthood, or hand enlargement after age 20. Those features require excess IGF-1 stimulation.

Sleep Apnea and Respiratory Burden

Sleep apnea occurs in 60 to 80% of acromegaly patients, driven by soft-tissue hypertrophy of the upper airway [6]. Andre's documented snoring, described in interviews by colleagues, is consistent. Untreated sleep apnea compounds cardiovascular risk substantially. In the context of acromegalic cardiomyopathy, uncontrolled nocturnal hypoxia may have accelerated his heart failure.

Modern Diagnosis: IGF-1, OGTT, and Pituitary MRI

A three-step diagnostic pathway now applies to any patient with clinical features of GH excess:

Step 1: Serum IGF-1

Draw a fasting serum IGF-1 and compare it to age- and sex-matched normative ranges. The Endocrine Society guideline recommends IGF-1 as the initial screening test [3]. An elevated IGF-1 in a symptomatic patient warrants further testing regardless of random GH levels, which fluctuate significantly throughout the day.

Step 2: Oral Glucose Tolerance Test with GH

Administer 75 g of oral glucose and measure GH at 0, 30, 60, 90, and 120 minutes. In healthy individuals, GH suppresses to <1 ng/mL (some guidelines use <0.4 ng/mL with ultrasensitive assays). Failure to suppress confirms autonomous GH secretion [3]. This test is the biochemical gold standard for diagnosis.

Step 3: Pituitary MRI with Gadolinium

Once biochemistry confirms GH excess, gadolinium-enhanced MRI of the sella identifies the adenoma and guides surgical planning. Macroadenomas (diameter greater than 10 mm) are present in approximately 75% of acromegaly patients at diagnosis [2]. Microadenomas are surgically more accessible and carry higher remission rates.

Treatment: What Would Have Been Available to Andre, and What Exists Now

Andre reached peak fame in the 1970s and 1980s. Transsphenoidal surgery had been refined by Jules Hardy in Montreal by that period, so surgical intervention was theoretically possible by the late 1970s. Octreotide was not FDA-approved until October 1988. Pegvisomant (Somavert) arrived in 2003.

Transsphenoidal Surgery

First-line treatment today is transsphenoidal adenomectomy, with remission defined as normalized IGF-1 and GH <1 ng/mL on OGTT at 12 weeks postoperatively. Remission rates reach 80 to 90% for microadenomas and 40 to 50% for macroadenomas in experienced centers [7]. The Endocrine Society guideline recommends surgery as initial therapy for most patients, with medical therapy reserved for those who are poor surgical candidates or who have disease that persists after surgery [3].

Somatostatin Receptor Ligands

Octreotide LAR (long-acting release, 10 to 40 mg IM monthly) and lanreotide autogel (60 to 120 mg subcutaneously every 4 weeks) normalize IGF-1 in 25 to 45% of patients on monotherapy [8]. A randomized trial of lanreotide autogel in 358 patients with active acromegaly (the PRIMARYS study) showed IGF-1 normalization in 38.5% at 48 weeks with 120 mg dosing [9].

These drugs bind somatostatin receptors subtypes 2 and 5 on tumor cells, suppressing GH secretion and, in some patients, reducing tumor volume. They are generally well tolerated, though gallstone formation occurs in up to 25% of long-term users [8].

Pegvisomant

Pegvisomant (Somavert) is a GH receptor antagonist, not a GH suppressant. It blocks GH action at the receptor and thereby lowers IGF-1. It normalizes IGF-1 in over 90% of patients when used at doses of 10 to 30 mg subcutaneously daily [10]. Because it does not suppress GH, tumor monitoring with MRI every 6 to 12 months is required. It is indicated for patients with persistent disease after surgery and inadequate response to somatostatin analogues.

Radiation Therapy

Stereotactic radiosurgery (Gamma Knife) is reserved for patients with residual tumor after surgery who cannot tolerate or have failed medical therapy. Biochemical remission occurs in 17 to 82% of cases depending on the series, but the time to remission can be 5 to 15 years [7]. In the interim, medical therapy bridges the patient.

Mortality and Long-Term Outcomes

Standardized mortality ratio in acromegaly has historically been 1.5 to 2.0 compared to the general population, driven largely by cardiovascular and cerebrovascular disease [1]. A prospective analysis from the German Acromegaly Register (N=480) found that patients achieving GH levels <2.5 ng/mL had mortality ratios not significantly different from the general population [11].

Andre died at 46. Based on population data, a 46-year-old French man in 1993 had a life expectancy of roughly 34 more years. Whether treatment would have normalized his mortality risk is impossible to state with certainty. What the data do support is that biochemical control substantially reduces excess cardiovascular risk [11].

Recurrence Monitoring

After surgical remission, patients require IGF-1 testing every 6 months for the first 2 years, then annually thereafter. Pituitary MRI is repeated at 12 months post-surgery and then every 1 to 2 years based on clinical status [3]. Clinicians who inherit acromegaly patients from other practices should request all prior operative and biochemical records before assuming ongoing remission.

Counseling Patients Who Bring Up Andre the Giant

Patients sometimes present asking "Could I have what Andre the Giant had?" after seeing a documentary or social media content about him. Take that question seriously. A brief symptom review costs nothing:

• Has shoe size changed in adulthood?
• Has ring size increased?
• Any new jaw pain or tooth spacing?
• Hyperhidrosis beyond what the patient considers normal?
• Snoring with witnessed apneas?
• Headaches localized to the front of the skull?
• Fatigue that does not resolve with sleep?

Two or more of these in a patient over 20 years old warrants serum IGF-1 testing. The Endocrine Society explicitly endorses this low-threshold approach: "We recommend against establishing the diagnosis of acromegaly using a single random GH measurement" and advises using IGF-1 as the starting point [3].

The Cost of Not Diagnosing

A German retrospective study found mean diagnostic delay of 6.8 years in acromegaly, with each additional year of delay associated with increased risk of structural cardiac abnormality on echocardiography [2]. Patients who go undiagnosed do not present with a dramatic transformation visible to a clinician in a single visit. The changes are gradual, and many patients and their families normalize them over time, much as Andre's colleagues reported thinking his appearance was simply his natural build.

When to Refer

Refer to endocrinology whenever IGF-1 is elevated above the age-sex reference range. Do not wait for a confirmed adenoma on MRI. If you see a pituitary lesion incidentally on imaging ordered for another reason, check IGF-1 before concluding the lesion is non-functional.

Acromegaly vs. Gigantism: Clarifying the Terminology for Patients

Andre's case spans both diagnoses, and patients often conflate them. Pituitary gigantism occurs when GH excess begins before epiphyseal closure, producing excessive longitudinal bone growth. Acromegaly is the term for GH excess that begins after epiphyseal closure. Both share the same etiology (almost always a pituitary somatotroph adenoma) and the same biochemical fingerprint (elevated IGF-1, failure of GH suppression on OGTT) [4].

Andre's height indicates GH excess began in childhood or early adolescence. His continued somatic changes into adulthood, including jaw enlargement and soft-tissue hypertrophy, reflect the acromegalic phase that followed. He had both conditions sequentially.

This distinction matters clinically because patients with gigantism who survive into adulthood require the same biochemical monitoring and treatment as acromegaly patients. The IGF-1 target, GH targets, and cardiovascular surveillance requirements are identical [3].

Differentiating from Constitutional Tall Stature

Constitutional tall stature does not change adult facial bone architecture, does not progress, and is not associated with elevated IGF-1. A tall patient with a family history of tall stature and no acral or facial changes does not need acromegaly workup unless symptoms develop. The key discriminating features are progression of hand or foot size in adulthood and soft-tissue changes, not height alone.

The Intersection of GH Axis Disorders and Sleep Medicine

Obstructive sleep apnea is so common in acromegaly that the American Academy of Sleep Medicine and endocrinology guidelines both recommend polysomnography in all newly diagnosed acromegaly patients [6]. GH itself has bidirectional effects on sleep architecture. Slow-wave sleep drives endogenous GH secretion, and in acromegaly, the normal nocturnal GH pulse is replaced by disordered, continuous secretion.

For clinicians managing sleep patients, any patient with severe OSA and no clear anatomical explanation (not obese, no tonsillar hypertrophy, no craniofacial abnormality) should have serum IGF-1 checked. The prevalence of acromegaly in unselected sleep clinic populations is estimated at 0.1 to 0.3%, roughly 10 to 30 times the population prevalence of acromegaly overall [6].

Andre's public-domain accounts describe extremely loud snoring and apparent nocturnal respiratory events. His cardiovascular trajectory, congestive heart failure at 46 despite no reported history of hypertension or coronary disease in available biographical sources, is consistent with acromegalic cardiomyopathy compounded by sleep-disordered breathing.